- Home
- GEHC vs HBANZ Comparison
GEHC vs HBANZ Comparison
Compare GEHC & HBANZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GEHC | HBANZ |
|---|---|---|
| Founded | 1892 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Major Banks |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8B | 33.4B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | GEHC | HBANZ |
|---|---|---|
| Price | $74.96 | $21.38 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $91.17 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 52.9K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | ★ 4.84 | N/A |
| EPS | ★ 4.55 | N/A |
| Revenue | ★ $20,625,000,000.00 | N/A |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $4.50 | N/A |
| P/E Ratio | $16.94 | ★ N/A |
| Revenue Growth | ★ 4.84 | N/A |
| 52 Week Low | $57.65 | $21.17 |
| 52 Week High | $89.77 | $22.23 |
Technical Indicators
Market Signals| Indicator | GEHC | HBANZ |
|---|---|---|
| Relative Strength Index (RSI) | 31.26 | 49.49 |
| Support Level | $69.34 | $21.27 |
| Resistance Level | $78.39 | $21.83 |
| Average True Range (ATR) | 2.18 | 0.24 |
| MACD | -0.80 | -0.07 |
| Stochastic Oscillator | 3.70 | 8.33 |
Price Performance
Historical ComparisonAbout GEHC GE HealthCare Technologies Inc.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).